PMID: 9530663Apr 8, 1998Paper

Bone substitution materials. Current status and prospects

Der Orthopäde
J M Rueger

Abstract

For the treatment of bony defects of the human skeleton there are different options. If a defect has to be filled up, autogenous cancellous bone is recommended as the 'golden standard', i.e. the material of choice for such procedures, ignorant to the fact that autogenous bone transplants are not without consequences to the patient and that their harvesting and transplantation might be connected to certain complications. As an alternative, there have been attempts to implant bone replacement materials as a substitute for the autogenous tissue. Despite a longstanding history of research in this field up to now a clinically applicable alternative could not have been found. Aim of the article is to classify the different compounds recommended for bone replacement. After a description of the development of the materials in the different classes, the state of the art and today's knowledge of how the different materials elicite their effects, an outlook into possible future developments is given for each class. Finally recommendations for today's clinical use of the bone substitutes are presented.

Citations

Aug 31, 2006·Der Unfallchirurg·M Schieker, W Mutschler
Aug 5, 2008·Archives of Orthopaedic and Trauma Surgery·Christian K G SpiesSteffen Breusch
Dec 23, 2004·Mund-, Kiefer- und Gesichtschirurgie : MKG·R MaiU Eckelt
Jul 12, 2011·Journal of Materials Science. Materials in Medicine·Anika JonitzRainer Bader
May 30, 2002·Biomaterials·D TadicM Epple
Aug 11, 2005·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Christian H FlammeChristof Hurschler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.